Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
phase 3
Biotech
Despite ph. 3 miss, Alkeus sees path forward for eye disease med
Despite a phase 3 miss, Alkeus still sees a path forward for its oral eye disease asset.
Gabrielle Masson
Sep 17, 2024 10:58am
GSK's long-acting asthma drug halved attacks in phase 3
Sep 9, 2024 9:30am
Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal
Aug 8, 2024 10:48am
Pfizer faces phase 3 DMD fail after patient death
Jun 12, 2024 5:01pm
Acelyrin rebounds with psoriatic arthritis victory
Mar 11, 2024 10:59am
GSK antibiotic shows potential in gonorrhea ahead of UTI filing
Feb 26, 2024 7:32am
